Ofloxacin otic solution. A review of its use in the management of ear infections

Drugs

Volumn 58, Issue 3, 1999, Pages 509-531

  Simpson, Kerryn L ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; EAR DROPS; ERYTHROMYCIN; HYDROCORTISONE; MACROLIDE; NEOMYCIN; OFLOXACIN; POLYMYXIN B; PREDNISOLONE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAFURAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; EAR INFECTION; EXTERNAL OTITIS; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; ORAL DRUG ADMINISTRATION; OTALGIA; OTITIS MEDIA; OTORRHEA; OTOTOXICITY; PHARMACODYNAMICS; PROTEUS MIRABILIS; PRURITUS; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TINNITUS; TOPICAL DRUG ADMINISTRATION; TYMPANOSTOMY TUBE; VERTIGO;

EID: 0032888727     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958030-00019     Document Type: Review

References (123)

1. Eden AN, Fireman P, Stool SE. The rise of acute otitis media. Patient Care 1995 CM 15; 29: 22-46
2. Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 1997 Apr; 16: 449-56
3. Bojrab D, Bruderley T, Abdulrazzak Y, et al. Otitis externa. Otolaryngol Clin North Am 1996; 29: 761-82
4. Clark WB, Brook I, Bianki D, et al. Microbiology of otitis externa. Otolaryngol Head Neck Surg 1997; 116: 23-5
5. Sundström J, Jacobson K, Munck-Wikland H, et al. Pseudomonas aeruginosa in otitis externa: a particular variety of the bacteria? Arch Otolaryngol Head Neck Surg 1996 Aug; 122: 833-6
6. Dohar JE. Baseline pathogens in childhood otorrhea: OE vs AOM in children with tympanostomy tubes. CD-ROM summary of Dr. Dohar's presentation at the 7th International Congress of Pediatric Otorhinolaryngology, sent to Elsevier Science on June 9 for their International Congress Science (ICS 1180) CD-ROM. Daiichi Pharmaceutical Corporation, Fort Lee, NJ, (data on file)
7. Buonpane E. Focus on ofloxacin: an antimicrobial drug of the fluoroquinolone class. Hosp Formul 1990 Apr; 25: 389-401
8. Hooper DC. Quinolone mode of action - new aspects. Drugs 1994; 45 Suppl. 3: 8-14
9. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991 Nov; 42: 825-76
10. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmakoktnetic properties and therapeutic use. Drugs 1987; 33: 346-90
11. Onrust SV, Lamb HM, Barman Balfour JA. Ofloxacin: a reappraisal of its use in the management of genitourinary tract infections. Drugs 1998; 56 (5): 895-928
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Vol. 17, Villanova, PA: NCCLS. M100-S7
13. Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997 Nov; 123: 1193-200
14. Agro AS, Garner ET, Wright III JW, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998 Jul-Aug; 20: 744-59
15. Dohar JE, Garner ET, Nielsen RW, et al. Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. Arch Otolaryngol Head Neck Surg 1998; 125: 537-45
16. Goldblatt EL, Dohar J, Nozza RJ, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol 1998; 46: 91-101
17. Kim JH, Kang JA, Kim YG, et al. In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone. Antimicrob Agents Chemother 1997 Oct; 41: 2209-13
18. Kim JH, Choi KH, Kim JW, et al. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone. J Antimicrob Chemother 1998 Feb; 41: 223-9
19. Yamaguchi K, Domon H, Miyazaki S, et al. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob Agents Chemother 1998 Mar; 42: 555-63
20. Choi K-H, Hong J-S, Kim S-K, et al. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. J Antimicrob Chemother 1997 Apr; 39: 509-14
21. Iwasaki H, Miyazaki S, Tsuji A, et al. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy Basel 1995 Mar-Apr; 41: 100-12
22. Wakebe H, Imada T, Yoneda H, et al. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrob Agents Chemother 1994 Oct; 38: 2340-5
23. Aldridge KE, Ashcraft DS, Sanders CV. RP 59,500 (quinupristin/dalfopristin): a new streptogramin with potent activity against pencillin-resisiant Streptococcus pneumoniae. Adv Ther 1998 May-Jun; 15: 158-64
24. Rubio MC, Goñi P, Vergara Y, et al. Susceptibility of pencillin-resistance and pencillin-susceptible Streptococcus pneumoniae to newer antimicrobials [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998 Sep 24; San Diego 261
25. Jones RN, Marshall SA, Grimm H. Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and the United States. Diagn Microbiol Infect Dis 1997 Oct; 29: 87-94
26. Pfaller MA, Jones RN. Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagn Microbiol Infect Dis 1997 Nov; 29: 199-201
27. Gimeno C, Borja J, Navarro D, et al. In vitro interaction between ofloxacin and cefotaxime against Gram-positive and Gram-negative bacteria involved in serious infections. Chemotherapy Basel 1998 Mar-Apr; 44: 94-8
28. Montanari MP, Prenna M, Mingoia M, et al. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Chemotherapy Basel 1998 Mar-Apr; 44: 85-93
29. Liassine N, Bille J, Breer C, et al. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland. Scand J Infect Dis 1997; 29 (6): 615-21
30. Dembry LM, Roberts JC, Schock KD, et al. Comparison of in vitro activity of trovafloxacin against Gram-positive and Gram-negative organisms with quinolones and β-lactam antimicrobial agents. Diagn Microbiol Infect Dis 1998 May; 31: 301-11
31. Nakane T, Iyobe S, Sato K, et al. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother 1995 Dec; 39: 2822-6
32. Gaja M, Tateyama M, Inadome J, et al. Basic and clinical studies of pazufloxacin in respiratory infections [in Japanese]. Jpn J Chemother 1995 Sep; 43 Suppl. 2: 310-5
33. Kim M-Y, Oh J-I, Paek K-S, et al. In vitro activities of LB20304, a new fluoroquinolone. Arch Pharm Res 1996 Feb; 19: 52-9
34. von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. J Antimicrob Chemother 1996 Aug; 38: 259-63
35. Eliopoulos GM, Wennersten CB, Moellering Jr RC. Comparative in vitro activity of levofloxacin and ofloxacin against Gram-positive bacteria. Diagn Microbiol Infect Dis 1996 May; 25: 35-41
36. Fuchs PC, Barry AL, Brown SD, et al. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis 1996 Aug; 15: 678-82
37. Liu Y-C, Huang W-K, Cheng D-L. Antibacterial activity of cefpodoxime in vitro. Chemotherapy Basel 1997 Jan-Feb; 43: 21-6
38. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997 Mar; 41: 709-11
39. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs 1995; 49 Suppl. 2: 235-7
40. Rolston KVI, Ho DH, LeBlanc B, et al. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 15-22
41. Dembry LM, Farrel PA, Orcutt DR, et al. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 35-42
42. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroqinolone, against recent clinical isolates. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 43-9
43. Visalli MA, Bajaksouzian S, Jacobs MR, et al. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob Agents Chemother 1997 Jul; 41: 1475-81
44. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997 Jul; 41: 1594-7
45. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, Antimicrob Agents Chemother 1997 Aug; 41: 1818-24
46. Hoogkamp-Korstanje JAA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Grain-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 1997 Sep; 40: 427-31
47. Toma E, Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microbiol 1995 Jul; 33: 1712-5
48. Mirelis B, Navarro F, Miró E, et al. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin. Drugs Exp Clin Res 1995; 21 (4): 129-38
49. Watanabe A, Oizumi K, Matsuno K, et al. Antibiotic susceptibility of the sputum pathogens and throat swab pathogens isolated from the patients undergoing treatment in twenty-one private clinics in Japan. Tohoku J Exp Med 1995 Apr; 175: 235-47
50. Biedenbach DJ, Sutton LD, Jones RN. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother 1995 Oct; 39: 2325-30
51. Guinea J, Gargallo-Viola D, Robert M, et al. E-4695, a new C-7 azetidinyl fluoronaphihyridine with enhanced activity against gram-positive and anaerobic pathogens. Antimicrob Agents Chemother 1995 Feb; 39: 413-21
52. Biedenbach DJ, Jones KN. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. Antimicrob Agents Chemother 1995 Jul; 39: 1636-43
53. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and-resistant pneumococci. J Antimicrob Chemother 1995 Jan; 35: 230-2
54. Prosser BLT, Beskid G. Multicenter in vitro comparative study of flouroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diagn Microbiol Infect Dis 1995 Jan; 21: 33-45
55. Nishijima S, Namura S, Akamatsu H, et al. Activity of eight fluoroquinolones against methicillin-resistant Staphylococcus aureus isolated from cutaneous infections. Int J Antimicrob Agents 1994 Aug; 4: 147-9
56. Bourgeois F, Bingen E. Killing kinetics of five fluoroquinolones against Moraxella catarrhalis at clinically achievable concentrations. J Antimicrob Chemother 1994 Feb; 33: 364-5
57. Nishijima S, Nakagawa M, Tsuboi N, et al. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. J Int Med Res 1996 Jan-Feb; 24: 12-6
58. Dholakia N, Rolston KVI, Ho DH, et al. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994 Apr; 38: 848-52
59. Peterson LR, Cooper I, Willard KE, et al. Activity of twenty-one antimicrobial agents including I-ofloxacin against quinolone-sensitive and -resistant, and methicillin-sensitive and -resistant Staphylococcus aereus. Chemotherapy Basel 1994 Jan-Feb; 40: 21-5
60. Clement JJ, Tanaka SK, Alder J, et al. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother 1994 May; 38: 1071-8
61. Mirelis B, Miró E, Navarro F, et al. In-vitro activity of E-1695, a new fluoronaphthyridine antimicrobial agent. J Antimicrob Chemother 1994 May; 33: 1017-23
62. Alonso R, Aránguiz AF, Colom K, et al. Multicenter study of the in vitro activity of ofloxacin [in Spanish]. Rev Esp Quimioter 1994 Mar; 7: 52-6
63. Waites K, Rand K, Jenkins S, et al. Multicenter in vitro comparative study of fluoroquinolones after four years of wide-spread clinical use. Diagn Microbiol Infect Dis 1994 Mar; 18: 181-9
64. Yamane N, Jones RN, Frei R, et al. Levofloxacin in vitro activity: results from an international study with ofloxacin and ciprofloxacin. J Chemother 1994 Apr; 6: 83-91
65. Sobottka I, Neumann S, Laufs R. Comparative in vitro activity of fleroxacin, two other quinolones and three broad-spectrum beta-lactams using the E-Test. Chemotherapy Basel 1994 Sep-Oct; 40: 293-8
66. Gaillot O, Berche P. In vitro susceptibility to ciprofloxacin on bacterial strains isolated from chronic otitis and sinusitis [abstract]. 5th Int Symp New Quinolone 1994: Singapore, 10
67. Verbist L, Verhaegen J. Comparative in vitro activity of BAY Y3118 against selected species [abstract]. 5th Int Symp New Quinolone 1994: Singapore, 4
68. Ismaeel NA, Tayeb OS. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates. Microbios 1993; 74 (299): 147-54
69. Kocagöz S, Gur D, Nal S, et al. In vitro activity of CP-99,219 against clinical isolates [abstract]. 35th Int Conf Antimicro Ag Chemother 1995 Sep 17: 153
70. Ristow TA, Peterson LR, Kahn JB. In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia. Drugs 1995; 49 Suppl. 2: 246-9
71. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother 1994 Feb; 38: 369-70
72. Howard BMA, Pinney RJ, Smith JT. Post-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes. Chemotherapy Basel 1993 Jul-Aug; 39: 265-71
73. Goldstein FW, Velasquez J, Guerrier ML, et al. Comparative post-antibiotic effect (PAE) of ofloxacin (Oflo), ciprofloxacin (Cip) and sparfloxacin (Spar) at low concentrations against penicillin susceptible (Ps) and -resistant (Pr) S. pneumoniae [abstract]. 34th Int Conf Antimicro Ag Chemother 1994: Orlando, Florida, 120
74. Debbia EA, Pescc A, Schito GC. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens. Am J Med 1992 Apr 6; 92 Suppl. 4A: 45S-7S
75. Eady EA, Cove JH. Topical antibiotic therapy: current status and future prospects. Drugs Exp Clin Kes 1990; 16 (8): 423-33
76. Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl. 3: 15-23
77. Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones, J Antimicrob Chemother 1998 Aug; 42: 179-87
78. Thomson KS, Sanders CC. Dissociated resistance among fluoroquinolones. Antimicrob Agents Chemother 1994 Sep; 38: 2095-100
79. Barlow DW, Ducket LG, Kreig CS, et al. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol Stockh 1994 Mar; 115: 231-5
80. Aran J-M. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995; 112: 133-44
81. Dreschler WA, Hulst RJAM, Tange VD, et al. The role of high-frequency audiometry in early detection of ototnxicity. Audiology 1985; 24: 387-95
82. Black HE, Schaefer G, Regan K, et al. One month ototoxicity study of an otic solution of ofloxacin in the guinea pig. Daiichi Pharmaceutical Corporation. 1998. (Data on file)
83. Kato M, Akahane K, Shimoda K. Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. J Antimicrob Chemother 1997 Feb; 39: 269-71
84. Agro A, Garner ET. Single dose, double-blind, placebo-controlled, parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults without active otitis media. Daiichi Pharmaceutical Corporation. 1995, 1996. (Data on file). Study report, protocol 8280A-PRT004
85. Agro A, Garner ET, McClean PH. Single dose, double-blind, placebo-controlled, parallel group study to asses the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults with suppurative otitis media with otorrhea. Daiichi Pharmaceutical Corporation. 1995, 1996. (Data on file). Study report, protocol 8280A-PRT005
86. Ohyama M, Furuta S, Ueno K, et al. Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. Arch Otolaryngol Head Neck Surg 1999; 125: 337-40
87. AHFS drug information 1999. Betheseda, USA: American Society of Health-System Pharmacists, Inc., 1999: 2409-13
88. Klein JO. Otitis externa, otitis media, mastoiditis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. v. I. New York: Churchill Livingston Inc., 1995: 579-85
89. Berman S. Otitis media in children. N Engl J Med 1995 Jun 8; 332: 1560-5
90. Gates GA ed. Common ear infections: clinical challenges. Professional Postgraduate Services - Continuing Medical Education monograph. Daiichi Pharmaceutical Corporation; NJ, 1998 (Data on file)
91. Tong MCF, Woo JKS, Vanhasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol 1996 Apr: 110: 309-14
92. Yuen PW, Lau SK, Chau PY, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol 1994; 15 (5): 670-3
93. Agro AS. Review - Therapeutic usefulness of ofloxacin in ear infections. Clinical efficacy of ofloxacin otic solution in otilis media and otitis externa. Penetration - International update on levofloxacin and ofloxacin. Daiichi Pharmaceutical Corporation. 1998; (Data on file): 38-42
94. Pessey JJ. Ofloxacin 0.3% otic solution in the treatment of purulent otorrhea in post-radical mastoidectomy cavities and non-osteitic chronic otitis media [abstract]. 7th International Congress for Infectious diseases 1996 Jun 10: 78-9
95. Narcy P. Efficacy and safety of ofloxacin 0.3% otic solution in the treatment of purulent otorrhea in children with ventilating tubes, post-radical mastoidectomy cavities and non-osteitic chronic otitis media [abstract]. 7th International Congress for Infectious Diseases 1996 Jun 10; Hong Kong, 158
96. Baba S, Kobayashi T, Takasaka T, et al. Comparative dose-finding study ofloxacin otic solution in suppurative otitis media [in Japanese]. Jibi to Rinsho 1990; 36 Suppl. 3: 537-63
97. Sakagami M, Shiraishi T, Kubo T, et al. A comparative study of the effect of ofloxacin on acute otitis media and the acute exacerbation of chronic otitis media between oral medicine and otic solution [in Japanese]. Jibi to Rinsho 1994; 40 (6): 962-8
98. Suzuki K, Baba S. Antimicrobial ear drop medication therapy. Acta Otolaryngol Suppl Stockh 1996; 525: 68-72
99. Abes GT, Jamir J, Gloria-Cruz MT, et al. Comparative efficacy and safety of ofloxacin and polymixin otic drops for active chronic otitis media [abstract]. 20th International Congress of Chemotherapy 1997 Jun 29: 91
100. Baba S. A double-blind clinical trial of ofloxacin otic solution for the treatment of chronic suppurative otitis media and its acute exacerbations [abstract]. Eur J Clin Microbiol Infect Dis 1991 Spec. issue: 281-2
101. Kawabata I, Masuda N, Kondo R. Clinical evaluation of ofloxacin otic solution against otitis externa and myringitis [in Japanese]. Igaku Yakugaku 1992; 27 (5): 1328-35
102. Ohyama M, Nobori T, Shima T. Clinical efficacy of ofloxacin otic solution in pediatric patients with otitis media et externa [abstract]. Eur J Clin Microbiol Infect Dis 1991 Spec. issue: 279-80
103. Baba S. A clinical study ofloxacin otic solution on suppurative otitis media and otitis externa in children [abstract]. Eur J Clin Microbiol Infect Dis 1991 Spec. issue: 280-1
104. Kaga K, Ichimura K. A preliminary report: clinical effects of otic solution of ofloxacin in infantile myringitis and chronic otitis media. Int J Pediatr Otorhinolaryngol 1998 Jan; 42: 199-205
105. Sumitsawan Y, Prawatmuang W, Tharavichitkul P, et al. Ofloxacin otic solution as treatment of chronic suppurative otitis media and diffuse bacterial otitis externa. J Med Assoc Thai 1995 Sep; 78: 455-9
106. Supiyaphun P, Tonsakulrungruang K, Chochaipanichnon L, et al. The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: a clinico-microbiological study. J Med Assoc Thai 1995 Jan; 78: 18-21
107. Esposito S, D'Errico G, Noviello S. Oral ciprofloxacin (CP) vs topical ofloxacin (OFX) for treatment of chronic suppurative otitis media (CSOM). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998 Sep 24: 598
108. Özagar A, Koç A, Çiprut A, et al. Effects of topical otic preparations on hearing in chronic otitis media. Otolaryngol Head Neck Surg 1997; 17: 405-8
109. Miettinen S, Laurikainen EL, Johansson R, et al. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol 1997; Suppl. 529: 90-4
110. Swansou DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61-8
111. Gendeh BS, Gibb AG, Aziz NS, et al. Vancomycin administration in continuous amulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol Head Neck Surg 1998 Apr; 118: 551-8
112. Floxin otic (ofloxacin otic solution) 0.3%. Daiichi Pharmaceutical Corporation drug prescribing information
113. Froom J, Culpepper L, Jacobs M, et al. Antimicrobials for acute otitis media? A review from the International Primary Care Network. BMJ 1997 Jul 12; 315: 98-101
114. Sagraves R, Maish W. Therapy of acute otitis media: clinical and economic aspects. PharmacoEeonomics 1994 Sep; 6: 202-14
115. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from three randomized trials. J Pediatr 1994; 124: 355-67
116. Cates C. An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study. BMJ 1999 Mar 13; 318: 715-6
117. Lisby-Sutch SM, Nemec-Dwyer MA, Deeter RG, et al. Therapy of otitis media. Clin Pharm 1990; 9: 15-34
118. Dowell SF, Butler JC, Giebink GS, et al. Drug-resistant Streptococcus Pneumoniae Therapeutic Working Group. Acute otitis media: management and surveillance in an era of pneumococcal resistance a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999 Jan; 18: 1-9
119. Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am 1995 Jun; 42: 509-17
120. Consensus panel examines the role of otopical antibiotics. American Acadamy of Otolaryngnlogy Head and Neck Surgery Bulletin 1999; 18 (6): 9
121. Halpern MT, Palmer CS, Seidlin M. Treatment patterns for otitis externa. J Am Board Fam Pract 1999; 12: 1-7
122. Merifield DO, Parker NJ, Nicholson NC. Therapeutic management of chronic suppurative otitis media with otic drops. Otolaryngol Head Neck Surg 1993; 109: 77-82
123. Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Am J Otol 1993; 14 (2): 141-6